NBQX disodium salt

Research use only, not for human use.

Potent, selective and competitive AMPA receptor antagonist. Neuroprotective and anticonvulsant; active in vivo.

NBQX is an AMPA receptor antagonist. NBQX blocks AMPA receptors in micromolar concentrations (~10–20 μM) and also blocks kainate receptors. In experiments, it is used to counter glutamate excitotoxicity. NBQX was found to have anticonvulsant activity in rodent seizure models. As the disodium salt, NBQX is soluble in water at high concentrations (at least up to 100 mM).(In Vitro):NBQX (FG9202) has a high affinity for AMPA and kainate binding sites with little or no affinity for the glutamate recognition site on the NMDA receptor complex.(In Vivo):NBQX (FG9202; 20 mg/kg, i.p.; for 3 days) decreases seizures induced by PTZ.NBQX is neuroprotective in a focal ischaemia model in the rat when given as an i.v. bolus dose of 30 mg/kg at the time of MCA occlusion and again at 1 h post occlusion.

——

Animal Model:Male Wistar rats that weighed 220-240 g with pentylenetetrazole (PTZ)Dosage:20 mg/kg Administration:IP; for 3 days Result:Effectively reversed the behavioral abnormality of epileptic seizures of chronic PTZ administration (50mg/kg; i.p.; for 28 days) in rats.

NBQX

GPCR/G Protein

PAR

AMPA

Neurological Disease

——

118876-58-7

336.28

C12H8N4O6S

>98% (HPLC)

DMSO : ≥ 75 mg/mL. 223.03 mM; H2O : < 0.1 mg/mL

c1cc2c3c(cc(c2c(c1)S(=O)(=O)N)[N+](=O)[O-])[nH]c(=O)c(=O)[nH]3

2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline -7-sulfonamide

(-20℃)

With Ice Pack

≥ 2 years